MolNFT v1 · #82638 · protein
Crystal structures of rat vdr-lbd with R270L mutation
3VT5 · Vitamin D3 receptor: “Crystal structures of rat vdr-lbd with R270L mutation”. X-ray diffraction, 1 ligand (YI2), 3 pockets (best druggability 0.87). MolNFT v1 #82638 on GenesisL1: 3D structure, binding sites and pockets in GL1X.
- PDB
- 3VT5
- Type
- protein
- Length
- 251 residues
- Chains
- 2
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Vitamin D3 receptor; Coactivator peptide drip
- UniProt
- P13053
- Ligands
- YI2
- Pockets
- 3 · best druggability 0.87
Structure
x-ray diffraction · 2 distinct chains · 66% helix, 3% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Vitamin D3 receptor | protein | 240 | 66% helix, 3% strand | P13053 |
| C | Coactivator peptide drip | protein | 11 | 64% helix, 0% strand | — |
Ligands and binding sites
- YI2 · (1R,2E,3R,5Z,7E)-17-{(1S)-1-[(2-ethyl-2-hydroxybutyl)sulfanyl]ethyl}-2-(2-hydroxyethylidene)-9,10-secoestra-5,7,16-triene-1,3-diol · ligand · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 344 | 0.87 | 0.96 | 44 | YI2 |
| 2 | 141 | 0.43 | 0.75 | 22 | empty |
| 3 | 50 | 0.29 | 0.75 | 10 | empty |
Interfaces
1 interface between chains.
- A–C · 568 Ų buried · 7 hydrogen bonds · protein-protein
Compared structures
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P13053
- Elsewhere: RCSB PDB 3VT5 · PDBe 3VT5 · UniProt P13053
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.